246 related articles for article (PubMed ID: 19720758)
1. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.
Nguyen ML; Terzyan S; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Nov; 77(11):4714-23. PubMed ID: 19720758
[TBL] [Abstract][Full Text] [Related]
2. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
[TBL] [Abstract][Full Text] [Related]
3. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
[TBL] [Abstract][Full Text] [Related]
4. Anthrax lethal toxin (LeTx) neutralization by PA domain specific antisera.
Verma M; Suryanarayana N; Tuteja U; Thavachelvam K; Rao MK; Bhargava R; Shukla S
Toxicon; 2017 Dec; 139():58-65. PubMed ID: 28919458
[TBL] [Abstract][Full Text] [Related]
5. A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.
Wu G; Hong Y; Guo A; Feng C; Cao S; Zhang CC; Shi R; Tan Y; Liu Z
Antimicrob Agents Chemother; 2010 Nov; 54(11):4750-7. PubMed ID: 20713663
[TBL] [Abstract][Full Text] [Related]
6. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD
PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft SC; Weiss AA
Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
[TBL] [Abstract][Full Text] [Related]
8. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
[No Abstract] [Full Text] [Related]
9. N-fragment of edema factor as a candidate antigen for immunization against anthrax.
Zeng M; Xu Q; Hesek ED; Pichichero ME
Vaccine; 2006 Jan; 24(5):662-70. PubMed ID: 16157430
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
Kelly-Cirino CD; Mantis NJ
Infect Immun; 2009 Nov; 77(11):4859-67. PubMed ID: 19703971
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
Abboud N; Casadevall A
Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
[TBL] [Abstract][Full Text] [Related]
13. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
14. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
15. Detoxified lethal toxin as a potential mucosal vaccine against anthrax.
Xu Q; Zeng M
Clin Vaccine Immunol; 2008 Apr; 15(4):612-6. PubMed ID: 18256208
[TBL] [Abstract][Full Text] [Related]
16. Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
Oscherwitz J; Yu F; Jacobs JL; Cease KB
Clin Vaccine Immunol; 2013 Mar; 20(3):341-9. PubMed ID: 23283638
[TBL] [Abstract][Full Text] [Related]
17. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
[TBL] [Abstract][Full Text] [Related]
18. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.
Crowe SR; Garman L; Engler RJ; Farris AD; Ballard JD; Harley JB; James JA
Vaccine; 2011 May; 29(20):3670-8. PubMed ID: 21420416
[TBL] [Abstract][Full Text] [Related]
19. Investigation of a panel of monoclonal antibodies and polyclonal sera against anthrax toxins resulted in identification of an anti-lethal factor antibody with disease-enhancing characteristics.
Kulshreshtha P; Tiwari A; Priyanka ; Joon S; Sinha S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):185-93. PubMed ID: 26364143
[TBL] [Abstract][Full Text] [Related]
20. Role of toxin functional domains in anthrax pathogenesis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
